Genetic testing for hereditary melanoma and pancreatic cancer: A longitudinal study of psychological outcome

Psycho-Oncology

Volumn 22, Issue 2, 2013, Pages 276-289

  Aspinwall, Lisa G ^a   Taber, Jennifer M ^a   Leaf, Samantha L ^a   Kohlmann, Wendy ^b   Leachman, Sancy A ^b,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

anxiety; cancer; genetic testing; melanoma; oncology; pancreatic cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ANXIETY; ARTICLE; CANCER RISK; CONTROLLED STUDY; DEPRESSION; DISTRESS SYNDROME; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE COST; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PANCREAS CANCER; RISK ASSESSMENT;

ADULT; ANXIETY; DEPRESSION; FEMALE; GENES, P16; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LONGITUDINAL STUDIES; MALE; MELANOMA; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; UNITED STATES;

EID: 84873375009     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.2080     Document Type: Article

References (35)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
2. Florell SR, Boucher KM, Garibotti G, et al,. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005; 23: 7168-7177.
3. Goldstein AM, Chan M, Harland M, et al,. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44: 99-106.
4. Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann, G,. J. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 2009; 11: 265-278.
5. Kasparian NA, Meiser B, Butow PN, Job RF, Mann, GJ,. Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility. J Genet Couns 2006; 15: 433-447.
6. Riedijk SR, deSnoo FA, van Dijk S, Berman W, van Haeringen A, Silberg S, van Elderen TMT, Tibben A,. Hereditary melanoma and predictive genetic testing: why not? Psycho-Oncology 2005; 14: 738-745.
7. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, Leachman SA,. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 2008; 17: 1510-1519.
8. Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, Leachman SA,. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol 2009; 60: 745-757.
9. de Snoo F, Riedijk S, Tibben A, et al,. Genetic testing in familial melanoma: uptake and implications. Psycho-Oncology 2008; 17: 790-796.
10. Christensen KD, Roberts JS, Shalowitz DI, Everett JN, Kim SY, Raskin L, Gruber SB,. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev 2011 Mar; 20 (3): 522-529.
11. Hamilton JG, Lobel M, Moyer A,. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009; 28: 510-518.
12. Collins VR, Meiser B, Ukomunne OC, Gaff C, St John DJ, Halliday JL. The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genet Med 2007; 9: 290-297.
13. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, et al,. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94 (12): 894-903.
14. Vasen HF, Gruis NA, Frants RR, van dV, Hille ET, Bergman W, Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87: 809-811.
15. Chu D, Kohlmann W, Adler DG,. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. J Pancreas 2010; 11 (3): 203-212.
16. Parker J, Florell S, Alexander A, DiSario J, Shami P, Leachman S,. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol [serial online]. August 2003; 139 (8): 1019-1025.
17. Patenaude A, Julian-Reynier C,. Cancer genetic testing: current and emerging issues. Psycho-Oncology 2008; 17 (8): 733-736.
18. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, et al,. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258 (5085): 1148-1152.
19. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al,. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 1: 23-26.
20. Croyle RT, Smith KR, Botkin JR, Baty B, Nash J,. Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 1997; 16: 63-72.
21. Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, Amos CI, Frazier ML, Lynch PM,. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2005; 23: 1902-1910.
22. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67 (6): 361-370.
23. Snaith RP, Zigmond AS,. HADS: Hospital Anxiety and Depression Scale. Windsor: NFER Nelson; 1994.
24. Lerman C, Trock B, Rimer BK, Jepson C,. Psychological side effects of breast cancer screening. Health Psychol 1991; 10 (4): 259-267.
25. Cella D, Hughes C, Peterman A, Chang C-H, Keshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus A, Lerman C,. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol 2002; 21: 564-572.
26. Graham J,. Missing data analysis: making it work in the real world. Annu Rev Psychol 2009; 60: 549-576.
27. Schafer J, Graham J,. Missing data: our view of the state of the art. Psychol Methods 2002; 7 (2): 147-177.
28. Schafer JL,. NORM: multiple imputation of incomplete multivariate data under a normal model (for Windows 95/98/NT)[computer program]. Version 2. Available from http://www.stat.psu.edu/~jls/misoftwa.html; 1999.
29. Taber JM, Aspinwall LG, Kohlmann W, Dow R, Leachman SA,. Parental preferences for CDKN2A/p16 genetic testing of minors. Genet Med 2010; 13: 1-16.
30. Broadstock M, Michie S, Marteau, T,. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000; 8: 731-738.
31. Beran TM, Stanton AL, Kwan L, Seldon J, Bower JE, Vodermaier A, Ganz PA,. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal?, Ann Behav Med 2008; 36: 107-116.
32. Low CA, Bower JE, Kwan L, Seldon, J,. Benefit finding in response to BRCA1/2 testing. Ann Behav Med 2008; 35: 61-69.
33. Claes E, Evers-Kiebooms G, Denayer L, Decruyenaere M, Boogaerts A, Philippe K, Legius E,. Predictive genetic testing for hereditary breast and ovarian cancer: psychological distress and illness representations 1 year following disclosure. J Genet Couns 2005; 14: 349-363.
34. Lim J, Macluran M, Price M, Bennett B, Betow, P, the K ConFab Psychsocial Group. Short- and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns 2004; 13: 115-133.
35. Shiloh S, Koehly L, Jenkins J, Martin J, Hadley D,. Monitoring coping style moderates emotional reactions to genetic testing for hereditary nonpolyposis colorectal cancer: a longitudinal study. Psycho-Oncology 2008; 17: 746-755.